Treatment: Present Status and New Trends

  • J. H. Walter
  • J. E. Wraith


Improvements in the understanding of the biochemical and molecular basis of inborn errors have led to significant improvements in our ability to treat many of these disorders. Such improvements, coupled with an ability to make more rapid diagnoses and advances in general medical care, particularly intensive care, are resulting in better long-term prognosis for many patients. However, the rarity of individual disorders has often made it difficult or impossible to obtain sufficient data for evidence-based assessment of treatments. This should be kept in mind when considering the efficacy of particular therapies. Anecdotal reports of improvements should be reviewed critically, but it is equally important to remain open to new advances. This chapter discusses recent progress in the development of treatments. We have also included a list of medications (with recommended dosages) that may be used in the treatment of inborn errors (Table 5.1). Readers should refer to the relevant chapters for detailed information about the management of specific disorders and to Chap. 4, “Psychosocial Care of the Child and Family”, for discussion of the psychological consequences of treatment.


Enzyme Replacement Therapy Fabry Disease Gauche Disease Inborn Error Monohydrate Creatine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Acosta PB, Stepnick Gropper S, Clarke Sheehan N et al. (1987) Trace element status of PKU children ingesting an elemental4diet. JPEN J Parenter Enteral Nutr 11: 287–292PubMedCrossRefGoogle Scholar
  2. 2.
    Safos S, Chang TM (1995) Enzyme replacement therapy inENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. Artif Cells Blood Substit Immobil Biotechnol 23: 681–692PubMedCrossRefGoogle Scholar
  3. 3.
    Brown-Harrison MC, Nada MA, Sprecher H et al. (1996) Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 58: 59–65PubMedCrossRefGoogle Scholar
  4. 4.
    Pollitt RJ (1995) Disorders of mitochondrial long-chain fatty acid oxidation. J Inherit Metab Dis 18: 473–490PubMedCrossRefGoogle Scholar
  5. 5.
    Morris AA, Clayton PT, Surtees RA et al. (1997) Clinical outcomes in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 131: 938PubMedGoogle Scholar
  6. 6.
    Irons M, Elias ER, Abuelo D et al. (1997) Treatment of SmithLemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet 68: 311–314PubMedCrossRefGoogle Scholar
  7. 7.
    Moser HW (1995) Komrower lecture. Adrenoleukodystrophy: natural history, treatment and outcome. J Inherit Metab Dis 18: 435–447PubMedCrossRefGoogle Scholar
  8. 8.
    Davies SE, Iles RA, Stacey TE et al. (1991) Carnitine therapy and metabolism in the disorders of propionyl- CoA metabolism studied using 1H-NMR spectroscopy. Clin Chim Acta 204: 263–277PubMedCrossRefGoogle Scholar
  9. 9.
    De Sousa C, Chalmers RA, Stacey TE et al. (1986) The response to L-carnitine and glycine therapy in isovaleric acidaemia. Eur J Pediatr 144: 451–456PubMedCrossRefGoogle Scholar
  10. 10.
    Rutledge SL, Berry GT, Stanley CA et al. (1995) Glycine and L-carnitine therapy in 3-methylcrotonyl-CoA-carboxylase deficiency. J Inherit Metab Dis 18: 299–305PubMedCrossRefGoogle Scholar
  11. 11.
    Walter JH (1996) L-Carnitine. Arch Dis Child 74: 475–478CrossRefGoogle Scholar
  12. 12.
    Waber LJ, Valle D, Neill C et al. (1982) Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 101: 700–705PubMedCrossRefGoogle Scholar
  13. 13.
    Igisu H, Matsuoka M, Iryo Y (1995) Protection of the brain by carnitine. Sangyo Eiseigaku Zasshi 37: 75–82PubMedCrossRefGoogle Scholar
  14. 14.
    Jaeken J, Detheux M, Van Maldergem L et al. (1996) 3Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 74: 542–545Google Scholar
  15. 15.
    Vasiliauskas E, Rosenthal P (1994) Is acute fatty liver of pregnancy a metabolic defect? Am J Gastroenterol 89: 1908–1910PubMedGoogle Scholar
  16. 16.
    Stockler S, Isbrandt D, Hanefeld F et al. (1996) Guanidinoacetate methyltransferase deficiency: the first inborn error of creatinine metabolism in man. Am J Hum Genet 58: 914–922PubMedGoogle Scholar
  17. 17.
    Sullivan CA, Magann EF, Perry KGJ et al. (1994) The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets ( HELLP) in subsequent gestations. Am J Obstet Gynecol 171: 940–943Google Scholar
  18. 18.
    Bennett MJ, Weinberger MJ, Kobori JA et al. (1996) Mitochondria) short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: a new defect of fatty acid oxidation. Pediatr Res 39: 185–188PubMedCrossRefGoogle Scholar
  19. 19.
    Kreuder J, Otten A, Fuder H et al. (1993) Clinical and biochemical consequences of copper-histidine therapy in Menkes disease. Eur J Pediatr 152: 828–832PubMedCrossRefGoogle Scholar
  20. 20.
    Kaler SG, Buist NR, Holmes CS et al. (1995) Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol 38: 921–928PubMedCrossRefGoogle Scholar
  21. 21.
    Niehues R, Hasilik M, Alton G et al. (1998) Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest 101: 1414–1420Google Scholar
  22. 22.
    Holme E, Lindstedt S (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione). J Inherit Metab Dis 21: 507–517PubMedCrossRefGoogle Scholar
  23. 23.
    Platt FM, Butters TD (1998) New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol 56: 421–430PubMedCrossRefGoogle Scholar
  24. 24.
    Hamosh A, McDonald JW, Valle D et al. (1992) Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 121: 131–135PubMedCrossRefGoogle Scholar
  25. 25.
    Alemzadeh R, Gammeltoft K, Matteson K (1996) Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia. Pediatrics 97: 924–926PubMedGoogle Scholar
  26. 26.
    Matsuo S, Inoue F, Takeuchi Y et al. (1995) Efficacy of tryptophan for the treatment of nonketotic hyperglycinemia: a new therapeutic approach for modulating the N- methyl-Daspartate receptor. Pediatrics 95: 142–146PubMedGoogle Scholar
  27. 27.
    Saitoh S, Momoi MY, Yamagata T et al. (1998) Effects of dichloroacetate in three patients with MELAS. Neurology 50: 531–534PubMedCrossRefGoogle Scholar
  28. 28.
    Takanashi J, Sugita K, Tanabe Y et al. (1997) Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci 145: 83–86PubMedCrossRefGoogle Scholar
  29. 29.
    Elpeleg ON, Ruitenbeek W, Jakobs C et al. (1995) Congenital lacticacidemia caused by lipoamide dehydrogenase deficiency with favorable outcome. J Pediatr 126: 72–74PubMedCrossRefGoogle Scholar
  30. 30.
    Stacpoole PW, Barnes CL, Hurbanis MD et al. (1997) Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 77: 535–541PubMedCrossRefGoogle Scholar
  31. 31.
    Grabowski GA, Barton NW, Pastores G et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33–39PubMedGoogle Scholar
  32. 32.
    Zimran A, Elstein D, Levy-Lahad E et al. (1995) Replacement therapy with imiglucerase for type 1 Gaucher’s disease. Lancet 345: 1479–5480PubMedCrossRefGoogle Scholar
  33. 33.
    Allgrove J (1997) Biphosphonates. Arch Dis Child 76, 73–75CrossRefGoogle Scholar
  34. 34.
    Brady RO, Murray GJ, Oliver KL et al. (1997) Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 1oo:EnGoogle Scholar
  35. 35.
    Thomson D (5993) Miracle drug: only $350,000 a year. (Ceredase). Time 141:54–55Google Scholar
  36. 36.
    Hobbs JR, Hugh-Jones K, Barrett AJ et al. (1981) Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2: 709–712PubMedCrossRefGoogle Scholar
  37. 37.
    Peters C, Shapiro EG, Anderson J et al. (1998) Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 95: 2601–2608Google Scholar
  38. 38.
    Prockop DJ (5997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71–74Google Scholar
  39. 39.
    Van’t Hoff WG, Dixon M, Taylor J et al. (1998) Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr 132: 1043–1044CrossRefGoogle Scholar
  40. 40.
    Jamieson NV, Watts RW, Evans DB et al. (1991) Liver and kidney transplantation in the treatment of primary hyperoxaluria. Transplant Proc 23: 1557–1558PubMedGoogle Scholar
  41. 41.
    Gruessner RW (1998) Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I. N Engl J Med 338: 1924PubMedCrossRefGoogle Scholar
  42. 42.
    Nicolino MP, Puech JP, Kremer EJ et al. (1998) Adenovirusmediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen-storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. Hum Mol Genet 7: 1695–1702PubMedCrossRefGoogle Scholar
  43. 43.
    Blomer U, Naldini L, Kafri T et al. (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71: 6641–6649PubMedGoogle Scholar
  44. 44.
    Charache S (1993) Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies. Experientia 49: 126–132PubMedCrossRefGoogle Scholar
  45. 45.
    Dover GJ, Humphries RK, Moore JG et al. (1986) Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 67: 735–738PubMedGoogle Scholar
  46. 46.
    Charache S, Dover G, Smith K et al. (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the yd0-globin gene complex. Proc Natl Acad Sci USA 80: 4842–4846PubMedCrossRefGoogle Scholar
  47. 47.
    Rubenstein RC, Egan ME, Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F5o8-CFTR. J Clin Invest 100: 2457–2465PubMedCrossRefGoogle Scholar
  48. 48.
    Kemp S, Wei HM, Lu JF et al. (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 4: 1261–1268PubMedCrossRefGoogle Scholar
  49. 49.
    Martinez M, Vazquez E (1998) MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 51: 26–32PubMedCrossRefGoogle Scholar
  50. 50.
    Kjaergaard S, Kristiansson B, Stibler H et al. (1998) Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type IA. Acta Paediatr 87: 884–888PubMedCrossRefGoogle Scholar
  51. 51.
    Mayatepek E, Schroder M, Kohlmuller D et al. (1997) Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr 86: 1138–1140PubMedCrossRefGoogle Scholar
  52. 52.
    Ostman-Smith I, Brown G, Johnson A et al. (1994) Dilated cardiomyopathy due to type-II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid. Br Heart J 72: 349–353PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • J. H. Walter
  • J. E. Wraith

There are no affiliations available

Personalised recommendations